We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Propensity score-matched analysis compares venetoclax and azacitidine versus CAG for acute myeloid leukemia in unfit patients, highlighting treatment effectiveness.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: